Skip to main content

Telix Japan Signs MOU with ATOX to Use IRE ELiT 68Ge/68Ga-Generator for Phase I Study of Prostate Cancer Diagnostic Imaging

Written by Customer Service on . Posted in Public Companies.

TOKYO, July 27, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce it has entered a Memorandum of Understanding (MOU) with ATOX Co., Ltd. (‘ATOX’), the exclusive Japanese sales agent for Belgium company IRE ELiT’s 68Ge/68Ga-generator. Under the terms of the MOU, ATOX will provide the 68Ge/68Ga-generator for use in a Phase I clinical study of Telix’s 68Ga-PSMA-11 kit for prostate cancer imaging in Japanese patients.
Telix Pharmaceuticals Japan President Dr. Shintaro Nishimura stated, “Although the clinical utility of PSMA-11 for prostate cancer imaging is well understood worldwide and included in clinical practice guidelines1, to date no meaningful clinical research involving PSMA-11 has been undertaken in Japan. Hence, as Telix Japan plans the first clinical trial of PSMA-11 for prostate cancer imaging in Japan, we are delighted to have established this partnership with ATOX for the provision of the IRE ELiT 68Ge/68Ga-generator. We believe this is a great first step not only for both our companies, but also for prostate cancer patients in Japan.”ATOX President Mr. Toshikazu Yaguchi, added that, “I believe that Telix recognizes ATOX’s longstanding contributions to Nuclear Medicine in Japan. ATOX looks forward to working with Telix Japan to ensure the realization of this important clinical trial and to improving the lives of Japanese patients living with prostate cancer.”About Telix Pharmaceuticals LimitedTelix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.comAbout ATOX Co., Ltd.By leveraging the business experience of investigational PET drug manufacturing in Kobe from 2011 to 2017, ATOX has been expanding its playing field to a nuclear medicine industry including the development of the Head PET device, import and sales of IRE ELiT’s 68Ge/68Ga generator and development of 224Ra/212Pb generator for alpha radionuclide therapy. For more information, visit https://www.atox.co.jp/en/Telix Japan ContactDr. Shintaro Nishimura
President & Chief Operating Officer
Telix Pharmaceuticals Japan K.K.
E: shintaro.nishimura@telixpharma.com
W: www.telixpharma.comATOX Contact
Shusaku Tazawa
Manager, Business Development Department
ATOX Co., Ltd.
E: shusaku_tazawa@atox.co.jp
W: https://www.atox.co.jp/en/
____________________________1 Trabulsi EJ, et al. Optimum Imaging Strategies for Advanced Prostate Cancer; ASCO Guideline. J Clin Oncol 38: 1963 – 1996 (published online January 15, 2020).

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.